Sobrino-García Miriam, Moreno Esther M, Muñoz-Bellido Francisco J, Gracia-Bara Maria T, Laffond Elena, Doña Inmaculada, Martín Cristina, Macías Eva M, de Arriba Sonia, Campanón Valle, Gallardo Alicia, Dávila Ignacio
Allergy Service, University Hospital of Salamanca, Salamanca, Spain.
Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Front Pharmacol. 2020 Nov 30;11:584633. doi: 10.3389/fphar.2020.584633. eCollection 2020.
Being labelled as allergic to different drugs results in patients receiving other treatments, which are more toxic, less effective and more expensive. We aimed to analyze different studies of the costs of drug hypersensitivity assessment. A bibliographic search on studies regarding this issue was performed, including the available scientific evidence up to June 2020. We searched three databases with terms related to costs and allergy testing in drug hypersensitivity reactions. Our search revealed 1,430 publications, of which 20 met the inclusion criteria. In the manuscript, prospective studies evaluating the costs of the evaluation of patients with suspected allergy to beta-lactams or non-steroidal anti-inflammatory drugs are analyzed. Also, comment is made on the costs associated with incorrect labeling as non-steroidal anti-inflammatory drug or penicillin hypersensitivity. Taking all costs into account, the study of drug hypersensitivity is not expensive, particularly considering the economic and clinical consequences of labeling a patient with hypersensitivity to drugs.
被标记为对不同药物过敏会导致患者接受其他治疗，而这些治疗毒性更大、效果更差且费用更高。我们旨在分析不同药物超敏反应评估成本的研究。对有关该问题的研究进行了文献检索，包括截至2020年6月的现有科学证据。我们用与药物超敏反应中成本和过敏测试相关的术语搜索了三个数据库。我们的搜索共找到1430篇出版物，其中20篇符合纳入标准。在本手稿中，分析了评估疑似对β-内酰胺类药物或非甾体抗炎药过敏患者的成本的前瞻性研究。此外，还对与非甾体抗炎药或青霉素过敏的错误标记相关的成本进行了评论。考虑到所有成本，药物超敏反应的研究并不昂贵，尤其是考虑到将患者标记为药物过敏所带来的经济和临床后果。
